Overall survival (OS) and progression-free survival (PFS) to CPB followed by bevacizumab maintenance therapy was correlated to tumor tracer uptake, quantified using peak standardized uptake values (SUVpeak).
Partway through study implementation, allocation to methadone maintenance therapy was changed from randomization to participant choice; randomization to HHRP-M continued throughout.
No additional or maintenance therapy was given.
No maintenance therapy was given as part of this study.
Maintenance therapy was considered a separate treatment line.
Clopidogrel maintenance therapy was recommended for 1 year after intervention.
The overall results suggested that maintenance therapy was beneficial, though the results were not statistically significant.
The study also demonstrated that pemetrexed maintenance therapy was well tolerated [ 34].
No maintenance therapy was used once the score rose to ⩾50.
Meanwhile, engagement in methadone maintenance therapy was independently and positively associated with optimal adherence to ART.
In a second study, paclitaxel maintenance therapy was administered following carboplatin/paclitaxel induction therapy [ 40, 41].
